Product

Olopatadine Hydrochloride

1 clinical trial

1 indication

Indication

Allergic Conjunctivitis

Clinical trial

PHASE IV, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, CONTROLLED,60 DAYS, PARALLEL GROUPS, SUPERIORITY STUDY, TO COMPARE THE EFFECTIVENESS AND TOXICITY OF BEPOTASTINE 1.5% PF vs. OLOPATADINE 0.2% WITH BAK IN TREATMENT OF ALLERGIC CONJUNCTIVITIS

Status: Completed, Estimated PCD: 2022-08-18